tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Travere Therapeutics price target raised to $32 from $30 at Wedbush

Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the shares. The firm notes Q2 update represented another strong showing for Filspari with Travere reporting a Filspari beat. With PSFs continuing to show growth, Wedbush thinks this bodes well for the forward revenue trajectory.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1